When Australia became the first country to permit authorised psychiatrists to prescribe MDMA and psilocybin for specific mental health conditions in July 2023, the global conversation centred on regulation.
Could these therapies work? Would psychiatrists embrace them? How quickly would psychedelic-assisted treatment move from clinical trials into everyday practice?
Three years later, a different question is beginning to shape the industry’s future.
Who will pay for it?
The answer may ultimately determine whether psychedelic-assisted therapies become part of mainstream mental healthcare or remain accessible only to patients able to fund treatment themselves.
While regulatory milestones continue to attract headlines, Australia’s private health insurance sector may be laying the foundations for an equally important shift.
Reimbursement is often the real inflection point
Healthcare innovation rarely reaches widespread adoption simply because regulators approve a new treatment.
History shows that reimbursement is often the catalyst that transforms promising therapies into routine clinical care.
That is why Medibank’s decision to fund eligible members participating in psychiatrist-led mental health programs for Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) deserves close attention.
The insurer initially launched the initiative in Western Australia before expanding it into Queensland, Victoria, New South Wales and the ACT through partnerships with specialist providers including Emyria’s Empax clinics and Avive Health.
The programs combine psychiatric assessment, structured psychotherapy and, where clinically appropriate, ketamine-assisted psychotherapy within an integrated model of care.
Importantly, Medibank is not reimbursing a medicine alone.
It is funding an evidence-based treatment pathway.
That distinction could prove significant for the future of psychedelic medicine.
Funding the treatment, not just the drug
Unlike conventional pharmaceuticals, psychedelic-assisted therapies rely on far more than the medicine itself.
Preparation sessions, psychiatrist oversight, psychologists, specialist nursing staff, monitored dosing sessions and integration therapy all contribute to both cost and clinical outcomes.
This creates a challenge for insurers.
Traditional reimbursement models are designed around medications or hospital procedures rather than multidisciplinary care delivered over several weeks.
Australia’s emerging approach suggests insurers may instead evaluate the complete therapeutic program rather than focusing solely on the drug being administered.
That model could ultimately prove more relevant for psychedelic-assisted therapies than reimbursement frameworks built around pharmaceuticals alone.
A potential blueprint for the sector
Insurance coverage for ketamine treatment already exists in parts of the United States, although reimbursement remains fragmented and varies considerably between providers and clinical settings.
Australia’s approach differs by supporting integrated mental health programs delivered through specialist providers rather than isolated treatment sessions.
The Department of Veterans’ Affairs has also begun funding eligible veterans through Emyria’s network, signalling growing interest from public as well as private healthcare funders in new models of mental health reimbursement.
While still early, these developments suggest payers are beginning to assess innovative psychiatric treatments using the same health economics framework applied to other areas of medicine: clinical outcomes, long-term patient benefits and overall healthcare costs.
Why the industry should be watching
For companies developing psychedelic medicines, reimbursement may ultimately prove more commercially important than regulation.
Regulatory approval determines whether a therapy can legally be prescribed.
Insurance determines whether patients can realistically access it.
Without reimbursement, treatment costs running into several thousand dollars remain a significant barrier for many Australians.
Broader insurance support could expand the addressable patient population, provide greater certainty for clinic operators and create a more sustainable commercial environment for companies investing in psychedelic-assisted care.
It may also encourage further investment in specialised clinics, workforce training and supporting healthcare infrastructure.
The next milestone
The industry’s next major breakthrough may not come from another Therapeutic Goods Administration decision.
Instead, attention is likely to shift towards Australia’s other major health insurers.
If additional insurers begin funding structured psychiatrist-led treatment programs incorporating novel therapies such as ketamine—and eventually other evidence-based psychedelic-assisted treatments—it could accelerate the transition from niche clinical services to mainstream mental healthcare.
Australia was the first country to introduce a regulated pathway for prescribing MDMA and psilocybin.
It may also become one of the first to demonstrate how reimbursement can support the broader adoption of innovative psychiatric care.
For the psychedelic sector, that could prove just as significant.
